TY - JOUR
T1 - Familial neurofibromatosis type 1
T2 - Clinical experience with DNA testing
AU - Hofman, Karen J.
AU - Boehm, Corinne D.
N1 - Funding Information:
The gene for NF-1 has been mapped to chromosome 17ql 1.24, 5; portions of it have now been cloned. 6, 7 Since 1989, closely linked DNA markers have made accurate di- Supported by a grant from the National Neurofibromatosis Foundation, Inc., New York, N.Y. Submitted for publication April 5, 1991; accepted Oct. 3, 1091. Reprint requests: Karen J. Hofman, MBBCh, Blalock 1008, Johns Hopkins University School of Medicine, 600 N. Wolfe St., Baltimore, MD 2120.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1992/3
Y1 - 1992/3
N2 - To determine how DNA testing for familial neurofibromatosis type 1 (NF-1) would be used in a clinical setting by patients and physicians, we performed confirmatory DNA testing on 24 individuals with a family history of NF-1 and on nine couples who requested DNA testing for current or future prenatal diagnosis. A further eight families were unsuitable for DNA linkage testing because of their pedigree structure. For the majority of persons the certainty of the test result was 95% to 99%. In five individuals, only one of whom was less than 6 years of age, the DNA-based diagnosis was discrepant with the clinical diagnosis at the time of referral. In all five cases, results of subsequent clinical reexaminations were consistent with the DNA diagnosis. We conclude that DNA testing by linkage analysis may be most useful as an adjunct to the clinical diagnosis of familial NF-1 (1) in children less than 6 years of age in whom the full manifestations may not yet be apparent, (2) in NF-1 families interested in prenatal testing, and (3) when the resources available for a complete clinical examination are limited.
AB - To determine how DNA testing for familial neurofibromatosis type 1 (NF-1) would be used in a clinical setting by patients and physicians, we performed confirmatory DNA testing on 24 individuals with a family history of NF-1 and on nine couples who requested DNA testing for current or future prenatal diagnosis. A further eight families were unsuitable for DNA linkage testing because of their pedigree structure. For the majority of persons the certainty of the test result was 95% to 99%. In five individuals, only one of whom was less than 6 years of age, the DNA-based diagnosis was discrepant with the clinical diagnosis at the time of referral. In all five cases, results of subsequent clinical reexaminations were consistent with the DNA diagnosis. We conclude that DNA testing by linkage analysis may be most useful as an adjunct to the clinical diagnosis of familial NF-1 (1) in children less than 6 years of age in whom the full manifestations may not yet be apparent, (2) in NF-1 families interested in prenatal testing, and (3) when the resources available for a complete clinical examination are limited.
UR - http://www.scopus.com/inward/record.url?scp=0026500241&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026500241&partnerID=8YFLogxK
U2 - 10.1016/S0022-3476(05)80903-5
DO - 10.1016/S0022-3476(05)80903-5
M3 - Article
C2 - 1347082
AN - SCOPUS:0026500241
SN - 0022-3476
VL - 120
SP - 394
EP - 398
JO - The Journal of pediatrics
JF - The Journal of pediatrics
IS - 3
ER -